AI Drug Discovery Startup Iambic Therapeutics Files for IPO

07:06 PM EDT, 09/21/2026 (MT Newswires) -- Nvidia (NVDA)-backed Iambic Therapeutics, an AI-driven drug discovery company, on Monday filed with the Securities and Exchange Commission for an initial public offering of common stock, seeking to list on the Nasdaq Global Select Market under the symbol "IAM." The number of shares and price range have not yet been set, the company said, adding that J.P. Morgan, Jefferies, BofA Securities and Citigroup are lead underwriters on the offering. The company reported a net loss of $77.3 million for 2025 and $50.1 million for the first half of 2026, with an accumulated deficit of $245.3 million as of June 30, 2026. Since inception, Iambic has raised approximately $461.8 million in capital, including from investors NVIDIA Corporation, Coatue Ventures, Nexus Venture Partners and Qatar Investment Authority's Q Healthcare Holding.